M-A | P2Y12 inhibitors show superior efficacy over aspirin for secondary prevention in CAD

P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Related:

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis – The Lancet (link to abstract – $ for full-text)

RCT | Clopidogrel is better than Aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

Meta-analysis of randomized trials: Clopidogrel is better than aspirin for the secondary prevention of cardiovascular events.

#ACC21 – RCT: Clopidogrel better than aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

Commentary on Twitter

Given superior efficacy & similar overall safety, #P2Y12 inhibitor monotherapy might be preferred over #aspirin monotherapy for long-term secondary prevention in pts w/ established #cvCAD. https://t.co/EehIEuWqOt#JACC #P2Y12i #CardioTwitter @FeliceGragnano @vlgmrc @Drroxmehran pic.twitter.com/betLycXGs5

— JACC Journals (@JACCJournals) July 5, 2023